



Goldsite Diagnostics Inc.

No. 103C, 503C & 504D, Technology Building & No. 3A & 4A, Technology Building Annex, Zhaoshang Sub-District, Nanshan District, Shenzhen, China, 518067
service@goldsite.com.cn

Product Statement for Ability of Detection of Main Variants

January 9th, 2023

To whom it may concern,

Our antibody epitope targeting on the N protein for SARS-CoV-2 is 44-178. With the pandemic outbreak of COVID-19, multiple SARS-CoV-2 virus variants have emerged, including Alpha (B.1.1.7), Beta (B.1.351), Gamma(P1), Delta(B.1.617.2), Epsilon(B.1.427/B.1.429), Zeta(P.2), Eta(B.1.525), Theta(P.3), Iota (B.1.526), Kappa(B.1.617.1), Lambda(C.37), Mu (B.1.621), Delta plus (AY.4.2), Omicron(B.1.1529, BA.1, BA.2, BA.2.12.1, BA.3, XE, BA.4, BA.4.6, BA.5, BA.2.75, BA.2.75.3, BF.1, BF.7, BA.5.1.7, BA.4.6, XBB, XBB 1.5, BQ.1.1, BA.5.2, XBC), etc.

According to our biological analysis and evaluation, GOLDSITE SARS-COV-2 Antigen Kit (Colloidal Gold), SARS-CoV-2 & Influenza A/B Antigen Kit (Colloidal Gold), SARS-CoV-2 & Influenza A/B & RSV Antigen Kit (Colloidal Gold), all target the N protein of the Covid virus. Most of the virus variants (including the XBB 1.5, BQ1.1, BA.5, BF7, etc.) contain mutations on another viral protein, the S protein. Therefore, our kit's performance is unaffected when detecting these variants mentioned.

GOLDSITE will continuously monitor the emergence of strains using the available information. Should new SARS-CoV-2 variants appear which affect the sensitivity of above-mentioned kits, we will immediately report this to customers while we continue to evaluate any related performance issues with our devices. If you have any questions on the provided information, please contact: service@goldsite.com.cn. Thank you for your support.

Goldsite Diagnostics Inc.

